Israeli Startup Develops AI Platform for Precise Genetic Drug Delivery
Translated & summarized from Mignews by baba
Israeli startup Undecimal Bio has created the DELiveri AI platform for precise delivery of genetic drugs to diseased cells, overcoming a key challenge in targeted therapy. The system uses machine learning and combinatorial chemistry to analyze molecular properties and optimize delivery to specific tissues, not just the liver. The company has raised $18 million in seed funding and will initially focus on treating cardiovascular and kidney diseases.
The story in 5 lines · by baba
- Israeli startup Undecimal Bio created the DELiveri AI platform for precise genetic drug delivery.
- The platform uses AI and combinatorial chemistry to target diseased cells beyond the liver.
- This technology aims to overcome a major barrier in delivering genetic medications.
- The company raised $18 million in seed funding for clinical programs.
- Initial applications will target severe cardiovascular and kidney diseases.
Israeli startup Undecimal Bio has developed an AI-powered platform named DELiveri, designed to precisely deliver genetic medications directly to diseased cells. This innovation addresses a major challenge in modern medicine by enabling drugs to target only the affected areas.
RNA interference-based drugs can block the function of damaged genes and halt the progression of severe diseases. However, current pharmaceutical methods face a significant physical barrier, as most delivery mechanisms can only effectively target liver tissues, leaving other vital organs inaccessible for precise therapy.
The DELiveri platform overcomes this limitation by combining combinatorial chemistry with machine learning. Instead of manual trial-and-error, the system analyzes vast chemical libraries. Living cells act as sensors, precisely detecting the delivery of the active substance. Autonomous AI algorithms process this data instantly, identifying correlations between molecular structure and penetration ability, and then model optimal formulas for specific tissues.
Undecimal Bio's leadership considers precise logistics crucial for advancing personalized gene therapy. According to co-founder and CEO Yaniv Ehrlich, the primary difficulty with such drugs has always been delivering the active substance to the correct bodily location, rather than suppressing the defective gene itself.
The company has secured $18 million in seed funding to scale the platform and initiate clinical trials. Initial applications of the technology will focus on treating severe cardiovascular and kidney diseases, where targeted access to affected cells is critical.
The same event, reported separately by each outlet. Open a few to compare what different newsrooms emphasize — and what they leave out.
Other 2
